Respiratory Disease Research
The respiratory system consists of the lungs, airways, diaphragm, trachea (windpipe) and pharynx (throat) and its primary function is the exchange of oxygen and carbon dioxide- breathing in and out. Between 6 and 10 liters of air are brought in and out of the lungs and 0.3 liters of oxygen are transferred from the alveoli to the blood per minute.
Respiratory Disease Research Products Areas
Products for Respiratory Disease Research - Page 18
- Cat.No. Product Name Information/Activity
-
BCC6667
AG 99
(E)-AG 99 ((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) is a potent EGFR inhibitor.
-
BCC5120
AV-412 free base
AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
-
BCC7356
BIBU 1361 dihydrochloride
Selective inhibitor of EGFR-kinase
-
BCC1449
Canertinib dihydrochloride
Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM.
-
BCC7667
CGP 52411
CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease.
-
BCC1306
3,3'-Diindolylmethane
3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.
-
BCN5499
Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
-
BCC7300
GW 583340 dihydrochloride
1173023-85-2
-
BCC7441
HDS 029
881001-19-0
-
BCC6046
HKI 357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.


